In the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the Zhejiang Cancer Hospital's biospecimen bank between 2012-2019, and obtained relevant clinical information. The gastric cancer tissues were subjected to transcriptomic, metabolomic and other multi-omics testing, and analyzed for the metabolic changes of gastric cancer, and proposed to discover relevant therapeutic targets.

Inclusion Criteria:

• 18≤age≤80
• Histologically or cytologically confirmed gastric cancer
• Undergo surgery for radical or palliative gastric cancer (both open and laparoscopic)
• Patients with survival follow-up information

Exclusion Criteria:

• Two or more kinds of malignant tumors at the same time
• Incomplete or missing case information
• Preoperative diagnosis of residual gastric cancer

These cases have histologically or cytologically confirmed gastric cancer and there are no other tumors

This study does not involve drug clinical trials but focuses on ensuring the confidentiality of patient information. To protect patient privacy, a coding system was used instead of real names when entering patient information such as names and ages. Each patient was assigned a study identification number upon enrollment. Throughout the entire study, only the main researchers in the research team have the authority to access the true personal data of patients obtained from the electronic database (such as names and ages), and it is strictly prohibited to circulate or share this information. During the publication of the research article, the main researchers in the research team will use sample coding to replace patient privacy information (such as names) to achieve de-identification. Additionally, the protection of personal information for study participants must be maintained throughout the entire research process, and it is strictly forbidden to circulate or leak such information.